Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-1-aminoindane] or saline (controls). Both doses of rasagiline markedly increased the survival of dopaminergic neurons in the lesioned substantia nigra, compared to controls (+97% and +119%, respectively). Treatment with the lower dose of rasagiline also abolished the motor stereotypies associated with nigrostriatal lesion. Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD).
Blandini
F
F
Laboratory of Functional Neurochemistry, Neurological Institute C. Mondino, 27100, Pavia, Italy. fabio.blandini@mondino.it
Armentero
M T
MT
Fancellu
R
R
Blaugrund
E
E
Nappi
G
G
D000818:Animals; D002452:Cell Count; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D016896:Treatment Outcome; D014446:Tyrosine 3-Monooxygenase / Q000096:biosynthesis
D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; C031967:rasagiline; D014446:Tyrosine 3-Monooxygenase